Skip to main content
Profile picture for Joel Kremer

Joel Kremer

Joel Kremer graduated from Temple University School of Medicine where he was elected to Alpha Omega Alpha, and trained in Internal Medicine and Rheumatology at Albany Medical Center Hospital, and Albany Medical College. He joined the faculty there in 1979, and became a full professor in 1990 when he assumed the title of Head of the Division of Rheumatology. In 2000, he became Director of Research at The Center for Rheumatology in Albany, NY and is the Pfaff Family Professor of Medicine at the Albany Medical College. He regularly teaches fellow and residents. His research interests have been in the area of therapeutics in patients with rheumatoid arthritis, as well as dietary intervention in this area. He has published extensively on methotrexate and more recently on biologic and small molecule therapeutic trials for RA and Comparative Effectiveness. He is the recipient of the Engalaticheff Award given by The Arthritis Foundation for “contributions which improve the quality of life of patients with arthritis” in 1997, and is a 2013 Master of the ACR. He is the author of over 230 peer-reviewed manuscript publications, 20 chapters and 6 texts. He is founder of Corrona, LLC and CMO of that organization. He is President of the CORRONA Research Foundation.

 

Articles By Joel Kremer

liveVote2.jpg

Methotrexate and Folate Use by Rheumatologists - Survey Results

The February 2017 RheumNow “Live Vote” surveyed US and non-US rheumatologists about their beliefs and practices regarding folic acid and methotrexate (MTX) use. A total of 495 responses were tabulated in 2 weeks. Here are the results, and comments from Dr. Kremer on his preferred answers to these questions.

Read Article

Methotrexate: Where it All Began

It’s somewhat bizarre that a designer drug from over 65 years ago would become the cornerstone of treatment for rheumatoid arthritis in the 21st century. When Sidney Farber designed a molecule that would interfere with folate metabolism in the middle of the 20th century, he was looking for a ubiquitous antimetabolite to treat cancer. Farber was actually quite concerned with the potential side effects of a drug that competitively inhibits folate metabolism. That is part of the reason he combined the “met” for metabolism with an “x”. The x was found on poison bottles and he thought it wise to include it in the name of this agent.  

Read Article
×